CombiMatrix Hires R. Weslie Tyson, M.D., as Chief Medical Officer
March 10 2014 - 6:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that veteran pediatric pathologist R. Weslie Tyson, M.D. (Wes), has
been hired as Chief Medical Officer, effective April 8, 2014. Dr.
Tyson, 56, will report directly to CombiMatrix President and CEO
Mark McDonough.
He will replace Richard D. Hockett, Jr., M.D., as Chief Medical
Officer, whose resignation was disclosed in a Form 8-K filed with
the Securities and Exchange Commission on February 24, 2014.
Dr. Tyson has been a practicing pediatric and perinatal
pathologist for 24 years, and has practiced perinatal and pediatric
pathology in the Denver community for the past 20 years. He was
with The Children's Hospital in Denver from 1993 to 1998. He comes
to CombiMatrix from UniPath, a multispecialty pathology group that
staffs eight metro hospitals and a large central laboratory. Dr.
Tyson founded the Pediatric/Neonatology section of UniPath and has
directed the pediatric and perinatal service for UniPath since
1999.
"We continue to add talent to an already outstanding medical
team and are very pleased to welcome to our executive team a
pediatric pathologist with Dr. Tyson's background and passion for
preventing recurrent pregnancy loss, who also understands the
demands of clinicians," McDonough said. "We believe Wes' background
and experience will be invaluable as we continue to execute our
strategy to establish a dominant position in the prenatal and
pediatric markets and become the premier independent laboratory
focused on delivering microarray technologies."
Dr. Tyson began his clinical practice at the Kosair Children's
Hospital and the University of Louisville and was there from 1990
to 1993.
He has published multiple articles, given extensive
presentations and has been recognized by families and peers for his
work and expertise in the area of perinatal pathology and poor
pregnancy outcome.
Dr. Tyson attended medical school at the University of Colorado
where he received his M.D. degree and also undertook his residency
in anatomic pathology. He spent a fourth year at the University of
Colorado Medical School specializing in clinical genetics followed
by a two-year fellowship in pediatric and perinatal pathology at
the University of British Columbia Women and Children's
Hospitals. He is a member of Phi Beta Kappa, Alpha Omega
Alpha, and the Society of Pediatric Pathology.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support to foster the highest
quality in patient care. CombiMatrix specializes in miscarriage
analysis, prenatal testing and pediatric genetics, offering
DNA‑based testing for the detection of genetic abnormalities beyond
what can be identified through traditional methodologies.
CombiMatrix performs genetic testing utilizing a variety of
advanced cytogenomic techniques, including chromosomal microarray,
standardized and customized fluorescence in situ hybridization
("FISH") and high-resolution karyotyping. CombiMatrix is dedicated
to providing high-level clinical support for healthcare
professionals in order to help them incorporate the results of
complex genetic testing into patient-centered medical decision
making. Additional information about CombiMatrix is available at
www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding management's future business,
operational and strategic plans, adding talent to our medical team,
and our strategy to establish a dominant position in the prenatal
and pediatric markets and become the premier independent laboratory
focused on delivering microarray technologies. These
forward-looking statements are not guarantees of future results and
are subject to risks, uncertainties and assumptions that could
cause our actual results to differ materially and adversely from
those expressed in any forward-looking statement. The risks
and uncertainties referred to above include, but are not limited
to: our ability to successfully expand the base of our
customers and strategic partners, add to the menu of our diagnostic
tests in both of our primary markets, develop and introduce new
tests and related reports, optimize the reimbursements received for
our microarray testing services, and increase operating margins by
improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, steadily increase the
size of our customer rosters in both prenatal and developmental
genetic testing markets; our ability to attract and retain a
qualified sales force in wider geographies and to attract and
retain a qualified medical team; rapid technological change in our
markets; changes in demand for our future services; legislative,
regulatory and competitive developments; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Relations / Media Contact:
Rene Caron
Allen & Caron, Inc.
Tel (949) 474-4300
rene@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2023 to Apr 2024